NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
Phase 2
Withdrawn
- Conditions
- Adenocarcinoma of the PancreasStage II Pancreatic CancerStage I Pancreatic CancerRecurrent Pancreatic CancerStage III Pancreatic Cancer
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00253526
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
Phase 2
Completed
- Conditions
- Adenocarcinoma of the Gastroesophageal JunctionMetastatic Gastric CancerAdvanced Unresectable Gastric Cancer
- Interventions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00253370
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
Phase 2
Completed
- Conditions
- Thyroid CancerDifferentiated Thyroid Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2013-02-04
- Target Recruit Count
- 34
- Registration Number
- NCT00251316
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Anabolic Steroids and Exercise in Hemodialysis Patients
Not Applicable
Completed
- Conditions
- End-Stage Renal DiseaseMuscle Weakness
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2010-01-14
- Target Recruit Count
- 80
- Registration Number
- NCT00250536
Reimbursement Effects on Enrollment in Obesity Treatment
Not Applicable
Completed
- Conditions
- Obesity
- Interventions
- Behavioral: Simulated insurance reimbursement
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2010-03-18
- Target Recruit Count
- 401
- Registration Number
- NCT00250510
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Development of Limited Contact CBT Treatment for IBS
Not Applicable
Completed
- Conditions
- IBS
- Interventions
- Behavioral: Minimal contact CBT (MC-CBT)Behavioral: Standard CBT (S-CBT)
- First Posted Date
- 2005-11-04
- Last Posted Date
- 2017-10-13
- Target Recruit Count
- 75
- Registration Number
- NCT00248586
- Locations
- 🇺🇸
UB, SUNY School of Medicine, Buffalo, New York, United States
Events Preceding Interstitial Cystitis (EPIC)
Completed
- Conditions
- Cystitis, Interstitial
- First Posted Date
- 2005-11-04
- Last Posted Date
- 2010-03-03
- Target Recruit Count
- 400
- Registration Number
- NCT00248664
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
Assessment of Insulin Production From Native Pancreas in Patients With Pancreas Transplants
Completed
- Conditions
- Pancreas TransplantLong-Functioning Pancreas Allografts
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 10
- Registration Number
- NCT00246844
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Phase 2
Completed
- Conditions
- Adult AngiosarcomaAdult NeurofibrosarcomaRecurrent Adult Soft Tissue SarcomaRecurrent Uterine SarcomaStage III Adult Soft Tissue SarcomaStage III Uterine SarcomaAdult Epithelioid SarcomaAdult LeiomyosarcomaStage IV Adult Soft Tissue SarcomaStage IV Uterine Sarcoma
- Interventions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 147
- Registration Number
- NCT00245102
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
Phase 2
Completed
- Conditions
- Recurrent Breast CancerMale Breast CancerStage IV Breast Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT00244881
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States